Glossary · EU medical devices: MDR
Benefit-risk determination (MDR)
Also known as: Benefit-risk analysis (MDR), Benefit-risk ratio, Benefit-risk balance
German: Nutzen-Risiko-Abwägung
Under the EU Medical Device Regulation (EU) 2017/745, the benefit-risk determination is the analysis of all assessments of benefit and risk of possible relevance for the use of the device for the intended purpose, when used in accordance with the intended purpose given by the manufacturer. It has to remain acceptable over the device's lifecycle.
- EU
- MDR
- IVDR
- Technical documentation
In one sentence
MDR benefit-risk determination (Art. 2(24)): weighing all benefits and risks of a device used as intended; it must stay acceptable over the lifecycle.
Example
For an implantable cardiac monitor, the manufacturer weighs earlier detection of arrhythmias (clinical benefit) against infection and migration risks; PMCF data on infection rates later update the determination in the clinical evaluation report.
Explained in context
This term is a station of a mini course
- The medical-device evidence chain: from intended purpose to post-market evidenceStation: Risk management fileStart the course
Context cards connect this term with others to answer one question. Also in British English and German.
- Risk management file owner: a functional roleWho keeps the risk management file of a medical device connected to the requirements, tests and warnings that depend on it?UKDeutsch
- The medical-device evidence chain: from intended purpose to post-market evidenceHow do the parts of a medical device’s technical documentation connect — and what has to be in place before an AI function may answer from it?UKDeutsch
How it applies
- Annex I Section 1: Risks must be acceptable when weighed against the benefits to the patient; GSPR 8 asks that known and foreseeable risks and side effects are minimized and acceptable against the evaluated benefits.
- Where it sits: Annex II Section 5 asks for the benefit-risk analysis and risk management in the technical documentation. The clinical evaluation provides the clinical benefits, the risk management file the residual risks.
- Lifecycle: Post-market surveillance and PMCF data update the determination; the PSUR reports its conclusions for class IIa and higher.
- Technical documentation: State the determination once, with its date and the evidence it rests on, and link it from the clinical evaluation report and the risk management report. If the two reports describe different benefits or different residual risks, the determination has no stable basis.
Benefit-risk determination vs. risk acceptability
Risk acceptability criteria in ISO 14971 judge individual risks and the overall residual risk; the MDR's benefit-risk determination puts all of them against the clinical benefit of the device as a whole. A risk can be within the manufacturer's criteria and the benefit-risk still be unfavorable if the claimed benefit is not supported.
External references
- Regulation (EU) 2017/745 (MDR) — Article 2(24), Annex I